Biosimilars: FDA Closes Out 2016 With Clinical Pharmacology Guidance
Executive Summary
While industry awaits US FDA guidance on interchangeability, agency finalizes document on clinical pharmacology data to support a demonstration of biosimilarity – years ahead of May 2019 target date in commitment letter for user fee program's renewal.